European Commission expands approved indications for subcutaneous infliximab biosimilar

The European Commission has extended approval for Celltrion Healthcare’s subcutaneous infliximab biosimilar to treat adults with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.Approved in 2019 for the treatment of DMARD-refractory rheumatoid arthritis, the subcutaneous version of Remsima (infliximab-dyyb, Celltrion) is intended to provide a more consistent drug exposure between patients as well as more convenient administration. With this approval, the subcutaneous formulation now matches all approved indications for the intravenousRead More

Share on facebook
Share on twitter
Share on linkedin